Ramucirumab

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Ramucirumab ^?

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	VEGFR2 (KDR)
Clinical data
Pregnancy cat.	?
Legal status	Investigational
Identifiers
CAS number	947687-13-0
ATC code	None
UNII	D99YVK4L0X
Chemical data
Formula	C6374H9864N1692O1996S46
Mol. mass	143.6 kDa
(what is this?)  (verify)

Ramucirumab (IMC-1121B)^[1] is a fully human monoclonal antibody (IgG1) being developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.
Ramucirumab is being tested in several phase III clinical trials for the treatment of breast cancer,^[2] metastatic gastric adenocarcinoma,^[3] non-small cell lung cancer,^[4] among other types of cancer.
This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.


=====================================================
RAMUCIRUMAB  IS REPORTED TO HAVE DEMONSTRATED OVERALL SURVIVAL BENEFIT IN SECOND LINE METASTATIC ESOPHAGEAL CANCER 5.2 MONTHS VS 3.8.  iT WAS TESTED AGAINST PLACEBO REPORTEDLY!  BRAVE PEOPLE!  BUT THE RESULT IS NOTICEABLE !  HYPERTENSION, ANEMIA AND FATIGUE WERE THE MOST COMMON SIDE EFFECTS HAPPENING GENERALLY IN IN LESS THAN 10% OF PATIENTS.

============================================================

WE HAVE SO MANY MEDICINE FOR MYELOMA, IT IS TIME TO TREAT THOSE WE HAVE OBSERVED SO FAR.  AND HIGH RISK  SMOLDERING MYELOMA CAN'T ESCAPE.  AT THE EUROPEAN CONGRESS ON HEMATOLOGIC MALIGNANCIES, THE SALVO HAS BEEN SHOT, HIGH RISK MYELOMA HAS BEEN REPORTED TO PROGRESS TO FULL BLOWN MYELOMA  IN A MEDIAN TIME OF 2 YEARS OR LESS.  SO TREATMENT SEEMS AN ATTRACTIVE OPTION! WITH A MEDIAN SURVIVAL OF 94%  vS 85%  FOR THOSE OBSERVED AFTER A 47 MONTH FOLLOW-UP!  WE ARE WAY INTO TREATING PATIENTS WE USED TO OBSERVE! REV-DEX WAS THE TREATMENT USED!